欧洲精品一区二区三区_欧美性性性性_国产一区二区免费在线播放_日日噜噜噜噜人人爽日本精品_无套中出丰满人妻无码_国产偷窥熟女精品视频大全

美國(guó)Atrium Medical
Atrium生產(chǎn)介入性心臟病學(xué)、放射學(xué)、胸部創(chuàng)傷護(hù)理、胸腔引流、血管外科和普通外科醫(yī)療設(shè)備技術(shù)。在過去的5年期間，Atrium醫(yī)療公司年均增長(zhǎng)達(dá)19%，其今年的銷售收入預(yù)計(jì)將達(dá)到或者略高于2億美元，此收購(gòu)將幫助加強(qiáng)公司的心臟設(shè)備業(yè)務(wù)。

Atrium醫(yī)療公司全球共有員工700人，其中450人工作在新罕布什爾的醫(yī)學(xué)科技總部。

    

“Hundreds of Atrium employees around the world enjoy a great sense of pride stemming from our commitment to quality, customer service and our passion for innovation. Recognizing that everything we do somehow touches the lives of millions of patients each year is further evidence of our commitment to quality.”

Steve Herweck
Founder, Chairman and CEO

Founded in 1981, Atrium is a diversified healthcare provider where improved patient outcomes is “job one” for every member of the firm. Workmanship in the quality products we build is reflected in Atrium’s worldwide demand for over 2.7 million sterile medical products manufactured and distributed to over 60 countries each year. Our commitment to ISO 13485 Quality Standards and pioneering discoveries in research, product development and manufacturing has enabled the company to excel in market leadership in nearly every healthcare segment we serve.

Atrium is a world class organization dedicated to innovation, research and development, state-of-the-art manufacturing, customer service, clinical education, professional marketing and sales, and global logistics. Atrium is a progressive business enterprise that experiences strong employee loyalty and long-term commitment and contributions. However, Atrium’s ambitious growth strategies in an evolving healthcare industry requires a constant pool of talented resources at all levels of the company.

From the cardiac cath-lab to the operating room, Atrium continues to invest in those leading edge technologies that best satisfy our financial goals and contribute to important advancements in patient care. Combining advanced automation with global manufacturing resources, together with extraordinary advances in biomaterial science, our diversified portfolio of critical care products are leading the way to brighter, more clinically effective solutions in cardiovascular disease, soft tissue repair and critical care management.